Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide.

@article{Wick2016LongtermAO,
  title={Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide.},
  author={Wolfgang Wick and Patrick Roth and Christian Hartmann and Peter Hau and Makoto Nakamura and Florian Stockhammer and Michael Christoph Sabel and Antje Wick and Susanne Koeppen and Ralf Ketter and Peter Vajkoczy and Ilker Y. Eyupoglu and Rolf Kalff and Torsten Pietsch and Caroline Happold and Norbert Galldiks and Friederike Schmidt-Graf and Michael Bamberg and Guido Reifenberger and Michael Platten and Andreas von Deimling and C. Meisner and Benedikt Wiestler and Michael Weller},
  journal={Neuro-oncology},
  year={2016},
  volume={18 11},
  pages={1529-1537}
}
BACKGROUND Optimal treatment and precise classification for anaplastic glioma are needed. METHODS The objective for long-term follow-up of NOA-04 is to optimize the treatment sequence for patients with anaplastic gliomas. Patients were randomized 2:1:1 to receive the standard radiotherapy (RT) (arm A), procarbazine, lomustine and vincristine (PCV) (arm B1), or temozolomide (TMZ) (arm B2). RESULTS Primary endpoint was time-to-treatment-failure (TTF), defined as progression after 2 lines of… CONTINUE READING